Vericel Corporation (NASDAQ: VCEL) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Vericel Corporation to related companies based on the strength of its risk, earnings, profitability, institutional ownership, analyst recommendations, valuation and dividends.

Institutional & Insider Ownership

33.8% of Vericel Corporation shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 3.3% of Vericel Corporation shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vericel Corporation and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel Corporation 0 0 3 0 3.00
Vericel Corporation Competitors 117 754 1615 58 2.63

Vericel Corporation presently has a consensus target price of $6.33, indicating a potential upside of 27.95%. As a group, “Biopharmaceuticals” companies have a potential upside of 6.57%. Given Vericel Corporation’s stronger consensus rating and higher possible upside, research analysts plainly believe Vericel Corporation is more favorable than its rivals.


This table compares Vericel Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel Corporation -50.27% N/A -59.46%
Vericel Corporation Competitors -13,404.97% 246.04% -20.09%

Volatility & Risk

Vericel Corporation has a beta of 3.17, indicating that its stock price is 217% more volatile than the S&P 500. Comparatively, Vericel Corporation’s rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vericel Corporation and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Vericel Corporation $53.77 million -$20.03 million -4.50
Vericel Corporation Competitors $579.30 million $241.72 million -6.59

Vericel Corporation’s rivals have higher revenue and earnings than Vericel Corporation. Vericel Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


Vericel Corporation rivals beat Vericel Corporation on 7 of the 12 factors compared.

About Vericel Corporation

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.